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ABSTRACT
Objectives: Potential thrombotic and antifibrinolytic influence of endometriosis on 
haemostasis has been recently reported in the literature, as well as increased cardiovascular 
morbidity in women suffering from the disease. We performed a pilot study to assess the 
influence of endometriosis on the thrombus formation process under in vitro flow conditions.
Material and methods: This study compared women with confirmed endometriosis (n = 23) 
surgically and control healthy subjects (n = 10). In both groups, the same exclusion criteria 
were used: a prior episode of thrombosis diagnosed as acquired or inherited thrombophilia, 
neoplasm, and an uncertain family history of thrombosis. We evaluated the whole blood 
thrombogenicity using T-TAS® at a shear rate of 240 s-1 (Total-Thrombus Analysis System, 
Zacros, Japan). 
Results: The blood clot formation initiation time (T10) and occlusion time (OT) were 
significantly shortened in the endometriosis group (p < 0.05). The area under the curve 
(AUC30) of blood clot time formation values (BCTF) was substantially higher in the patients 
suffering from a disease (p = 0.03). An increase in AUC (TTAS) values by 100 increases the 
risk of developing endometriosis by 1.56-fold [adjusted OR = 1.56 (p = 0.01);(95% CI: 1.10–
2.18)]. Inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), and the leucocyte, 
neutrophil, basophil, and neutrophil concentrations) were also substantially higher in the 
endometriosis group (p < 0.05). 
Conclusions: The alteration of the T-TAS and NLR values supports the thesis of a shift of the 
equilibrium towards thrombosis in women who have endometriosis. This phenomenon links 
to a state of chronic inflammation. It is detectable using a novel system for the quantitative 
assessment of the platelet thrombus formation process under flow conditions in vitro. 
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INTRODUCTION
Endometriosis is a disease defined by the occurrence of endometrial glands and stroma
outside the uterine cavity [1]. It remains a relatively prevalent gynaecological disorder. That 
disease affects from 6% to 10% of women of reproductive age in the United States of 
America [2]. 
Despite this, the aetiology of the disorder is still elusive [3]. A growing body of 
scientific evidence has recently been linking endometriosis with an immunologic dysfunction,
metabolic changes, the atherogenic lipid profile, oxidative stress as well as with chronic 
systemic inflammation [4, 5]. Moreover, this disease may be a significant risk factor for major
chronic diseases, although the underlying mechanism is not yet fully understood [6]. 
In contemporary research, an association of endometriosis with many common 
systemic comorbidities, such as cancers, allergy, autoimmune and cardiovascular diseases 
have been found [6–8]. Coronary heart disease (CHD) remains an example of arterial 
thrombosis, and in a large prospective study, laparoscopically confirmed endometriosis was 
associated with an increased risk of CHD episodes. That association was more influential in 
the younger group of women who have endometriosis. Moreover, 
hysterectomy/oophorectomy procedures and hormonal therapy increase the risk of CHD; 
however, those can only partially explain the link of CHD with endometriosis [9–11]. After 
adjustments for potential confounders, the relative risk of CHD in Endometriosis is 1.62-fold 
increased, in comparison to non-endometriosis women [6]. 
Various inflammatory factors such as intracellular adhesion molecule 1 (ICAM-1), 
interleukin-1 and interleukin-6 (IL-1 and IL-6), tumour necrosis factor-alpha α (TNF- α) and 
vascular endothelial growth factor (VEGF) and vitamin D polymorphism alteration have been
described in endometriotic patients [12–16]. The systemic inflammatory response results in 
changes in the white blood cells (WBC) and the coexistence of relative lymphocytopenia and 
neutrophilia has been observed [17, 18]. Thus, the increased ratio of neutrophil-to-lymphocyte
(NRL) in endometriosis women strongly suggests the occurrence of chronic inflammation in 
this group of patients [19]. In endometriosis, an increased level of activated macrophages and 
increased levels of the cytokines provides a local microenvironment suitable for the initiation 
and growth of endometriotic lesions [20]. 
A growing body of research supports the thesis that inflammation and haemostasis 
processes interact substantially with each other [21]. The coagulation modulates the 
inflammation, and the inflammation activates the coagulation cascade [22, 23]. The 
inflammatory response enhances and promotes the initiation of coagulation, increasing the 
risk of organ dysfunction and microvascular thrombosis [24, 25]. 
In endometriosis patients, the haemostasis and coagulation assay values are altered. In 
2015, Wu et al., proved that in women with endometriosis, the APTT (activated partial 
thromboplastin time), and TT (thrombin time) are shortened while the fibrinogen 
concentration is elevated. Moreover, in their blood, a higher percentage of circulating 
degranulated platelets was found [21]. Several studies have demonstrated that those changes 
are involved in the development of endometriosis. Endometriosis women appear to remain in 
a hypercoagulable and hypofibrinolytic state due to platelet aggregation in endometriotic 
lesions. It provides a potential rationale for the use of anticoagulants to treat endometriosis 
[26].
Platelet size is an essential marker of platelet function. Mean platelet volume (MPV) 
remains an indicator of platelet activation, and increased values link to platelet 
hyperreactivity. Thus, MPV is also an important biological variable predicting the risk of 
arterial micro thrombotic episodes such as vascular complications in diabetes mellitus. Liu et 
al., showed an association of MPV with the severity of diabetic retinopathy [27]. 
There are numerous methods for assessing haemostasis. However, screening 
coagulation assays are not sensitive enough to detect hypercoagulation adequately and thus 
remain unable to evaluate thrombotic risk [28]. Efforts have been made to use global, integral 
assays to mimic and reflect aspects of haemostasis in vitro. An example of such is the Total 
Thrombus-formation Analysis System (T-TAS®). This system enables the evaluation of the in
vitro thrombus formation process under flow conditions. (T-TAS®) is an innovative 
microchip flow-chamber system enabling quantitative assessment of the platelet thrombus 
formation process. This assay represents noteworthy improvements over conventional platelet
function assays. The fact that T-TAS is sensitive not only to platelet aggregation but also 
detects alterations occurring in the fibrinolytic system is very important considering the aim 
of our study [29]. 
Many previous studies have demonstrated the influence of endometriosis on some 
coagulation assays, but still, conventional coagulation assays are often not sensitive enough to
detect hypercoagulation and are unable to evaluate the risk of developing thrombosis. To date,
there has been no research study assessing the influence of endometriosis on the process of 
thrombus formation under flow conditions in vitro.
Our study aimed to evaluate the whole blood thrombogenicity in women who have 
endometriosis to assess in this pilot study the occurrence of any alteration of haemostasis in 
this group of women. 
MATERIAL AND METHODS
Subjects
We conducted the study in the Department of Reproduction at the Poznan University 
of Medical Sciences from December 2017 until March 2018. The analysis included 23 
patients with surgically confirmed endometriosis as well as 10 healthy women, who formed 
the control group. 
We collected the data of patients who were referred to the gynaecological ward due to 
a suspicion of endometriosis. All the patients from the endometriosis group suffered from at 
least one of the clinical symptoms and signs of the disease such as dysmenorrhea, dysuria, 
dyspareunia, dyschezia, subfertility, or infertility. 
We took a detailed history which included a list of varied gynaecological items from 
every subject in the control group. All women from this group presented regular monthly 
menses with standard length and denied using any medications, including oral contraceptives, 
in the previous 12 months. 
Every woman from the control group denied the occurrence of symptoms such as ever 
having been diagnosed or having a suspected diagnosis of endometriosis. 
Moreover, in both groups, the same additional exclusion criteria were used to avoid 
significant confounding factors, such as an episode of venous or arterial thrombosis in the 
prior history, diagnosed acquired or inherited thrombophilia, neoplasm and an uncertain 
family history of thrombosis, pregnancy, hypertension, smoking and the occurrence of any 
vascular disease.
Methods
Blood samples for all tests in both groups were taken in the follicular phase of the 
menstrual cycle. In patients undergoing surgical procedures, blood samples were taken a day 
before the scheduled surgery. 
Standard comparative laboratory findings
All biochemical tests were performed in the accredited laboratory of the University 
hospital (Central Laboratory, The Obstetrics and Gynecology Teaching Hospital of Poznan 
University of Medical Sciences), which holds an ISO 9000 certificate of quality management. 
We collected blood samples for standard conventional laboratory tests at the same time in a 
fasting state from the antecubital veins. 
After being drawn, the blood was collected in tubes containing 
ethylenediaminetetraacetic acid (EDTA). Ethylenediaminetetraacetic acid was used as an 
anticoagulant to prevent clotting. The samples we immediately transported to the laboratory. 
Testing was performed with the use of an automated flow cytometry haematology analyser 
(Roche Diagnostics ®).
T-TAS findings
Evaluation of whole blood thrombogenicity (assessment of the formation of a 
thrombus under flow conditions) was assessed immediately after taking the blood samples 
using T-TAS® at a shear rate of 240 s-1 (Total Thrombus Analysis System, Fujimori Kogyo, 
Zacros, Japan, AR-chip) equipped with AR microchip and thrombogenic surfaces (collagen 
with thromboplastin).
For each test, the patient blood samples were analysed for thrombus formation area 
under a flow pressure curve for 30 min (AUC30 indicates the area under the flow pressure 
curve for the 30 min.), time of blood clot formation initiation (T10) and OT or T80 (an 
occlusion time - time of complete thrombus formation inside the AR-chip). T80-T10 — time 
of growth of the thrombus on AR chip (duration between the time of initiation of formation of
the blood clot, and occlusion time). T10 is defined as the time of the onset of the formation of 
a thrombus. It resembles the duration of the flow pressure from baseline values to the ten kPa 
pressure values. It is related with the partial occlusion of the microcapillary. T80 (OT) 
represents the time of complete occlusion of the microcapillary, occurring with a pressure of 
80kPa. T80-T10 is the interval between T10 and OT or T80 and represents the rate of growth 
of a thrombus. AUC30 remains an area under the 80 kPa flow pressure curve for 30 min after 
the start of the assay in the AR chip. 
Statistical analysis
Statistical analysis was performed using PQ STAT® statistical software. For normality,
we checked the data using the Shapiro-Wilk test, and then appropriate parametric or 
nonparametric tests were used to assess the differences between the parameters across the two
groups. For parametric, independent samples, the t-Test for independent values and the 
nonparametric Mann-Whitney U test were used. We used Multivariate logistic regression to 
obtain the OR values. Due to the limited numbers of participants in the analysed groups, in 
multivariate logistic regression, the use of only one confounder (BMI) was plausible.
The values of the variables are presented as mean ± one standard deviation or median 
(interquartile range) appropriate to the use of nonparametric and parametric, respectively. A p-
value of < 0.05 was considered statistically significant. 
The study complies with the principles of the Declaration of Helsinki. The Ethics 
Committee approved the study protocol of the Poznan University of Medical Sciences 
(approval number 300/17, 2/3/2017).
We took informed written consent from all patients.
RESULTS
In this pilot study, we aimed to compare the whole blood thrombus formation process 
under flow conditions in endometriosis and healthy individuals. Beyond this, we performed 
conventional standard laboratory investigations in all groups. 
Total thrombus analysis system results 
The analysis carried out with the use of T-TAS showed that in women with 
endometriosis, the initiation of thrombus formation, and the total clot formation time inside 
the AR-chip occurred significantly faster compared to the control group. The T10 and OT 
values were significantly shorter between groups (p = 0.008; p = 0.003, respectively). 
The area under the flow pressure curve for 30 min (AUC) values was significantly 
higher in the endometriosis group compared to the controls (p = 0.009). 
Due to the limited number of participants in the analysed groups, in multivariate 
logistic regression, the use of only one confounder (BMI) was plausible. After analysis 
adjusted for BMI, a link between an increase by 100 in the AUC-30 values, and a 1.56-fold 
increased risk of endometriosis was demonstrated, adjusted OR = 1.56 [p = 0.01; 95% 
confidence interval (CI): 1.10–2.18].
Standard laboratory investigations 
We observed differences in the complete blood count (CBC) values in the study and 
control groups. In the endometriosis group, lower erythrocytes [red blood cells (RBC)], 
haemoglobin (HGB) concentrations, and the haematocrit value were observed (respectively: p
= 0.02, p = 0.0008; p = 0.03). The occurrence of those differences is caused mainly by the 
heavy menstrual bleeding reported by patients from the study group. 
Inflammation status analysis revealed substantially higher leucocytes [white blood 
cells (WBC)] (p = 0.002) as well as neutrophil (p = 0.00002) and basophils(p = 0.0008) 
concentrations in the study group. Additionally, we observed a statistically lower eosinophils 
concentration in the endometriosis group (p = 0.003). 
The neutrophil-to-lymphocyte ratio (NLR), which is as a marker of subclinical 
inflammation, was almost threefold higher in the endometriosis group compared to the 
healthy controls. This difference across those two groups was statistically significant (p = 
0.0001). 
Agranulocytes: the lymphocyte and monocyte concentrations did not differ across the 
groups. 
Additionally, there were no differences observed in the PLR (Platelet-to-lymphocyte 
ratio) between the groups in our study. PLR assessment is a novel index reflecting a systemic 
inflammatory burden that combines the prognostic values of an individual’s platelet and 
lymphocyte counts.
Our study group comprised of 23 surgically confirmed endometriosis patients. Revised
American Society for Reproductive Medicine classification (rASRM) of endometriosis to 
classify lesions during surgical procedures has been used. With I and II stage of endometriosis
were diagnosed 5 and with III and IV 18 patients, respectively. We used only rASRM. Due to 
non-parametric data median with 1st (lower) and 3rd (upper) quartile were reported in Table 1. 
(4; 3–4). 
Values and appropriate p-values are shown in Table 1. 
DISCUSSION
In the present study, we investigated the prothrombotic influence of endometriosis 
using a novel automated microchip flow chamber system for the quantitative analysis of 
thrombus formation: Total Thrombus-formation Analysis System (T-TAS®). To date, there 
has been no research study assessing the influence of endometriosis on the process of 
thrombus formation using this system, and no such data has been obtained in women who 
have endometriosis yet.
T-TAS enables the assessment of the whole blood thrombogenicity [29]. It was 
designed to evaluate the prophylaxis of various antiplatelet drugs against thrombosis, based 
on the phenomenon that platelets remain crucial to initiating thrombus formation. This system
further allows an evaluation of the in vitro thrombus formation process under flow conditions.
It is also useful in assessing the clot formation process in haemostasis alterations such as 
factor VIII deficiency (mouse model) [30]. Previous research on a T-TAS showed that the 
system might be useful in assessing the effects of antithrombotic agents [29, 31]. Before this 
study, the impact of endometriosis on haemostasis using T-TAS® had not been analysed.
Increased whole-blood thrombogenicity has been demonstrated in the Endometriosis 
group. 
Augmented blood clotting in those patients is not recognisable using a standard test 
such as mean platelet value (MPV). Moreover, the platelet count values were not different in 
the study and control groups. Therefore, our data strongly suggest that T-TAS might be a 
sensitive diagnostic tool to detect a prothrombotic state occurred in women who have 
endometriosis, however, our findings need further elucidation in research on significantly 
more extensive data sets to be confirmed.
There is a considerable body of evidence that endometriosis predisposes to alter the 
coagulation status in women [32]. Thus, our findings remain consistent with the literature. We
support the thesis of a shift towards thrombosis in the haemostasis milieu in that group of 
patients. Ding et al., showed a higher platelet aggregation rate, fibrinogen concentration, 
platelet activation rate, elevated plasma D-dimer, plasma soluble P-selectin, prothrombin 
fragment 1 + 2 (F1 + 2), fibrin degradation products and shortened thrombin time [33]. In a 
study conducted by Qinjiao et al., APTT and TT were shortened, and elevated fibrinogen 
levels were documented. The authors of this study suggested the possibility of a therapeutic 
role of anticoagulant agents and their potential future use in the treatment of endometriosis 
[21]. There are numerous studies with a suggestive role in the activation of the coagulation 
cascade in endometriosis. The potential role of a tissue factor, in the etiopathogenesis of the 
disease, has been demonstrated as an angiogenic parameter [34].
In this study, we documented that using the T-TAS system. We can detect a significant 
difference in the time of initiation, elongation and the total time of thrombus formation in 
healthy vs endometriosis subjects. Moreover, T-TAS not only detects differences in whole-
blood thrombogenicity mediated by platelet hyperreactivity but is also sensitive to alterations 
occurring in the fibrinolytic system. Our results support the thesis that endometriosis is 
associated with hyperfibrinolysis, and thus they remain consistent with prior research studies 
on this topic. The fibrinolytic system plays a significant role in maintaining homeostasis. It 
affects not only the haemostatic balance but also tumour invasion, tissue remodelling, 
reproduction and angiogenesis [35]. PAI-1 (plasminogen activator inhibitor-1) is a significant 
inhibitor of the fibrinolytic system [36]. A growing body of evidence indicates that increased 
levels of PAI-1 mediate tumour metastasis, diabetes, cardiovascular and reproductive diseases
[37][38][39][40]. Bedaiwy et al., showed that endometriosis is associated with 
hyperfibrinolysis due to the more frequent occurrence of the 4G allele of the PAI-1 gene in 
surgically confirmed endometriosis patients [15]. There is, however, a dispute in the link 
between PAI-1 polymorphic variants and susceptibility to endometriosis [41][42]. 
Hypofibrinolysis promotes a fibrin matrix, thus supporting the initiation of endometrial 
lesions in the peritoneal cavity caused by retrograde menstruation [15].
Moreover, in peritoneal fluid from patients with endometriosis, increased PAI-1 
antigen links with an increased risk of peritoneal adhesions [42]. PAI-1 regulates tumour cell 
migration and the mechanism of endometriotic cell invasion [43, 44]. This notion could be 
potentially a piece of the explanation of why some women develop the endometriosis 
phenotype while others do not [15]. PAI-1 4G/5G links with endometriosis-associated 
infertility [45]. PAI-1 antigenic levels were higher in ovarian endometriomas than in a normal 
eutopic endometrium [46]. In in vitro studies, endometrial stromal tissues sampled from 
women with endometriosis released higher PAI-1 antigen levels than tissues derived from a 
healthy control group. The higher release of PAI-1 might be an essential phenomenon in the 
invasive growth process which occurs in endometriotic lesion formation [43].
The chronic inflammatory process related to the increase of cytokines and chemokines
occurring in patients with endometriosis has been well demonstrated in previous research 
[47]. 
In our study, we showed a higher NLR (neutrophil-to-lymphocyte ratio) in women 
with endometriosis. Thus, our results remain consistent with prior research. Tokmak et al. 
[48], showed higher NLR values in endometriosis patients and stated that the combination of 
Ca-125 levels and NLR values improves diagnostic accuracy in detecting endometriomas. 
Cho. et al. [49], evidenced that NLR levels can discriminate endometriosis patients from 
controls with 83.9% specificity when combined with other markers such as Ca-125. Our study
fails to indicate MPV as a marker of platelet hyperreactivity in women with endometriosis. 
Our study group comprised of patients, who underwent surgery due to endometriosis. 
We have been struggling with defining the reasons for differences in CBC values across the 
analysed groups, therefore we have stated a hypothesis that those may be related with 
menstrual disorders, which are more plausible in women suffered from a disease. In authors’ 
opinion more studies are required to assess eventually plausible linkage between CBC and 
whole blood thrombogenicity measured by T-TTAS values alterations in women affected by 
endometriosis. Using this limited data, it is very difficult to answer the question whether CBC
alteration have affected T-TAS values unequivocally; what may be considered as a limitation 
of our study.
Summarising, our findings strongly support the thesis that endometriosis triggers a 
shift toward a prothrombotic and antifibrinolytic state, and this phenomenon can be detectable
using a novel microchip flow-chamber system for quantitative assessment of the platelet 
thrombus formation process under flow conditions in vitro. The results obtained by this 
system have shown that each increase in AUC (T-TAS®) values by 100 increases the risk of 
developing endometriosis by 1.56-fold. 
Due to the limited data and limited sample size of our study, the role of T-TAS 
alterations in endometriosis patients needs to further elucidation with much larger data sets in 
order to confirm our essential findings. 
CONCLUSIONS
The potential thrombotic and antifibrinolytic influence of endometriosis on 
haemostasis, as well as increased cardiovascular morbidity in women suffering from a 
disease, have recently been reported in the literature. 
T-TAS® (total thrombus formation analysis) is a useful diagnostic tool allowing the 
assessment of whole blood thrombogenicity. In our study, the (T-TAS®) results substantially 
differed in the endometriosis and healthy control groups. Blood clot formation initiation time 
and occlusion time were significantly shortened in endometriosis, which may indicate the 
prothrombotic state of this disease. The alteration of (T-TAS®), the NLR (neutrophil-to-
lymphocyte ratio) and the granulocytes concentration values in endometriosis support the 
thesis of a shift of the equilibrium towards thrombosis occurring in patients suffering from the
disease, as well as the plausible linkage of this phenomenon with the chronic inflammatory 
status also found in this group of patients. 
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4.45 4.33 4.65 4.07 3.99 4.47 0.02
RDW (RED CELL 
DISTRIBUTION 
WIDTH) [%]
12.95 12.38 13.35 13.10 12.25 13.45 0.16
MCV [fL] 85.26 3.08 85.11 5.34 0.96
MCH [fmol] 1.92 1.78 1.94 1.81 1.70 1.86 0.07
MCHC [mmol/L] 21.76 0.80 20.72 0.76 0.001
HGB [mmol/L] 8.32 0.61 7.44 0.63 0.0008
HCT [L/L] 0.38 0.02 0.36 0.03 0.03
LEUKOCYTES 
(WBC) [G/L]
6.18 4.82 6.55 9.88 6.22 12.02 0.002
NEUTROPHILES 
[G/L]
3.23 1.03 7.91 4.06 0.00002
EOZYNOPHYLES 
[G/L]
0.10 0.09 0.16 0.04 0.02 0.085 0.003
BASOPHYLES 
[G/L]
0.02 0.02 0.02 0.04 0.03 0.045 0.0008
LYMPHOCYTES 
[G/L]
1.88 0.68 1.66 0.55 0.33
MONOCYTES 
[G/L]
0.49 0.44 0.53 0.67 0.42 0.82 0.16
PLATELETS [G/L] 270.50 206.00 279.00 255.00 219.50 291 0.52








1.66 1.41 2.11 4.79 3.11 6.34 0.0001
ENDOMETRIOSIS 
STAGE
N/A 4 3 4 -
Comparative T-TAS findings
T10 [s] 639.40 284.07 325.70 165.45 0.008
AUC30 1468.65 398.35 1893.40 233.68 0.009
OT [s] 800.50 599.50 926.50 385.00 328.50 511 0.003
*Mean with SD (standard deprivation) are presented for parametric data. Median with 1st 
(lower) and 3rd (upper) quartile are reported for non-parametric data; **For parametric: 
independent-samples t-Test and for nonparametric U Mann-Whitney test were used; Note: 
Statistically significant p values are indicated in bold; BMI — body mass index; N/A — not 
applicable; RBC — red blood cells; HGB — haemoglobin; WBC — white blood cells; MPV 
— mean platelet volume; T10 — time of blood clot formation initiation; AUC30 — area 
under the curve; OT — occlusion time
